Tango Therapeutics Inc
NASDAQ:TNGX
Tango Therapeutics Inc
Net Income (Common)
Tango Therapeutics Inc
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Tango Therapeutics Inc
NASDAQ:TNGX
|
Net Income (Common)
-$101.7m
|
CAGR 3-Years
-846%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
4%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$484m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-20%
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$3.8B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income (Common)
$4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income (Common)
$3.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
26%
|
See Also
What is Tango Therapeutics Inc's Net Income (Common)?
Net Income (Common)
-101.7m
USD
Based on the financial report for Dec 31, 2023, Tango Therapeutics Inc's Net Income (Common) amounts to -101.7m USD.
What is Tango Therapeutics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
-846%
Over the last year, the Net Income (Common) growth was 6%. The average annual Net Income (Common) growth rates for Tango Therapeutics Inc have been -846% over the past three years .